[{"from": "human", "value": "Describe this molecule. [C][C@@H1][C][N][Branch1][=Branch2][C][C@@H1][Branch1][Ring2][O][Ring1][=Branch1][C][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][/C][=C][/C][=N][N][C][=C][Ring1][Branch1][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C@@H1][C][C@][Ring1][Ring1][C][=C][Branch1][O][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][O][C][N][C][Ring1][O][=O].[C][=Branch1][#Branch1][=C][/C][=Branch1][C][=O][O][\\C][=Branch1][C][=O][O]"}, {"from": "gpt", "value": "The molecule is an orally available fumarate salt form of CFI-400945, a polo-like kinase 4 (PLK4) inhibitor with potential antineoplastic activity. Upon oral administration, polo-like kinase 4 inhibitor CFI-400945 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. PLK4 inhibition also prevents cell division and inhibits proliferation of PLK4-overexpressing tumor cells. PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle."}]